Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02230202 · ClinicalTrials.gov registry record
Endothelial Microparticles: A Novel Marker of Vascular Dysfunction
A clinical trial of Chronic Kidney Disease, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 90
- Enrollment target
- 2
- Study locations
NCT02230202: Completed study of Chronic Kidney Disease, sponsored by University of Colorado, Denver.
NCT02230202 is a study of Chronic Kidney Disease that has completed, run by University of Colorado, Denver. The registered enrollment target is 90 participants, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02230202, a study of Chronic Kidney Disease, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 90 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary hypothesis of this proposal is that chronic kidney disease (CKD) and treatment with calcineurin inhibitors (CNIs) are each associated with the release of endothelial microparticles into the plasma.
Primary Outcome
This will be measured with flow-mediated dilation and evaluate percent change from baseline over minutes.
Conditions Studied
Interventions
- OTHER Flow-mediated dilation
- OTHER single blood draw
Study Locations (2)
Colorado
- University of Colorado Anschutz Medical Campus; CTRC - Aurora
- University of Colorado School of Medicine - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-03 |
What the finished NCT02230202 record still lists
NCT02230202 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Flow-mediated dilation is the first listed.
NCT02230202 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT02230202 about?
NCT02230202 is a clinical study titled "Endothelial Microparticles: A Novel Marker of Vascular Dysfunction". The primary hypothesis of this proposal is that chronic kidney disease (CKD) and treatment with calcineurin inhibitors (CNIs) are each associated with the release of endothelial microparticles into the plasma.
What is the current status of trial NCT02230202?
This trial is currently completed. The enrollment target is 90 participants. The study started on 2014-09. Estimated completion is 2016-03.
What conditions does trial NCT02230202 study?
This clinical trial studies the following conditions: Chronic Kidney Disease.
What interventions are being tested in trial NCT02230202?
The interventions under investigation include: Flow-mediated dilation (OTHER), single blood draw (OTHER).
Who is sponsoring clinical trial NCT02230202?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02230202 being conducted?
This trial has 2 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02230202's enrollment target sits among peer trials
90 61st of 101 higher than 40 of 101 other Chronic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
RECRUITING · Phase 2
-
Patient-driven Management of BP in CKD
RECRUITING · Phase 3
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Pivotal Study of the Velocity™ pAVF System
RECRUITING · NA
-
Safety of Short-course of NSAIDs in Pediatric Patients With CKD
RECRUITING · Phase 4
-
Intensive Patient Referral and Education Program Prior to Renal Replacement Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia